Confident Investing Starts With TipRanks Premium

Go Ultimate 55% OFF

The Income Fund of America - Class 529-T (TFAAX)

The Income Fund of America - Class 529-T (TFAAX) is a mutual fund that focuses on generating income for its investors. It invests in a diverse portfolio of fixed-income securities, such as bonds and money market instruments, as well as dividend-paying stocks. This fund is designed for investors who are seeking a steady stream of income and are willing to take on a moderate level of risk. With a ticker symbol of TFAAX, this fund is easily identifiable and can be a valuable addition to a well-rounded investment portfolio.

TFAAX Mutual Fund Chart & Stats

No data to display

Sub-Category: Income
Total Liabilities: $2.64B
Expense Ratio: 0.61%
Holding Count: 3,176
Brand: Income Fund Of America
Category: Fixed-Income
Total Assets: 149.18B
Shares Outstanding: N/A

TFAAX Mutual Fund News

Option traders moderately bearish in UnitedHealth with shares down 0.77%

Option traders moderately bearish in UnitedHealth (UNH), with shares down $3.13 near $406.25. Options volume roughly in line with average with 27k contracts traded and calls leading puts for a

56m agoUNH 0R0O

Gilead announces results from Phase 3 IDEAL study of livdelzi

Gilead (GILD) Sciences announced the detailed results from the Phase 3 IDEAL study, which demonstrated that the majority of participants living with PBC and treated with Livdelzi achieved the alkaline

2h agoGILD GIS

Amgen’s Repatha lowers heart attack risk 20% vs. ezetimibe in real-world study

Amgen (AMGN) announced results from a large real-world study showing that treatment with Repatha – evolocumab – reduced the risk of fatal or nonfatal heart attacks by 20% compared with

3h agoAMGN AMG

Amgen price target raised to $435 from $378 at Guggenheim

Guggenheim analyst Vamil Divan raised the firm’s price target on Amgen (AMGN) to $435 from $378 and keeps a Neutral rating on the shares. Published first on TheFly – the

4h agoAMGN AMG

Southern Company sees FY26 adjusted EPS $4.70, consensus $4.59

Previous guidance was $4.50-$4.60. Comments taken from investor presentation slides. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks

4h agoSO SOT

Southern Company sees Q4 EPS 30c, consensus 44c

07:36 EST Southern Company (SO) sees Q4 EPS 30c, consensus 44c Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot

4h agoSO SOT

Southern Company reports Q3 adjusted EPS $1.94, consensus $1.71

Reports Q3 revenue $8.84B, consensus $8.41B. “The Southeast is growing at a pace that is both unprecedented and transformational, and we believe Southern Company (SO) is well positioned for today

4h agoSO SOT

Amgen Earnings Call Highlights Growth, Pipeline Momentum

Amgen Inc (($AMGN)) has held its Q3 earnings call. Read on for the main highlights of the call. Amgen’s third-quarter call carried a strongly optimistic tone, with revenue up 8%,

17h agoAMGN AMG

Cboe data shows mixed options sentiment in UnitedHealth with shares up 0.99%

Cboe data shows mixed options sentiment in UnitedHealth (UNH), with shares up $4.02, or 0.99%, near $408.46. Options volume roughly in line with average with 48k contracts traded and calls

1d agoUNH 0R0O

Qualcomm (QCOM) Signs Multi-Year Deal to Supply 5G Network Gear for SpaceX’s Starlink Mobile

Qualcomm ($QCOM) signed a multi-year agreement on Wednesday to provide 5G cell tower hardware and software for SpaceX’s ($SPCX) upcoming Starlink Mobile wireless network across the United States. QCOM shares

1d agoAVGO INTC

Gilead’s GS-1206 Cancer Trial Advances as Investors Watch for Early Signals

Gilead Sciences ($GILD) announced an update on their ongoing clinical study. Study Overview: Gilead Sciences is studying GS-1206 in adults with solid tumors under the official title, “A Phase 1

1d agoGILD

Trump Trade: Democratic sweep hits political trades

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily

1d agoSO CEG

Amgen price target raised to $530 from $500 at Scotiabank

Scotiabank analyst Louise Chen raised the firm’s price target on Amgen (AMGN) to $530 from $500 and keeps an Outperform rating on the shares. The firm believes the company’s commercial

1d agoAMGN AMG

Amgen price target raised to $398 from $380 at Truist

Truist analyst Gregory Renza raised the firm’s price target on Amgen (AMGN) to $398 from $380 and keeps a Hold rating on the shares. The firm is positive on the

1d agoAMGN AMG

Top 10 Holdings

The fund's ten largest positions
Name	Weight %
USD_CASHCAPITAL GROUP CENTRAL CASH FUND	6.67%
PMPhilip Morris International	2.09%
AMGNAmgen Inc	1.80%
EOGEOG Resources Inc	1.72%
UNHUnitedhealth Group Inc.	1.58%
SOThe Southern Company	1.55%
AVGOBroadcom Inc.	1.53%
2330TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD	1.40%
GILDGilead Sciences	1.38%
SBUXStarbucks	1.36%
Total	21.08%

Go to Holdings >

Recently Viewed

No data currently available